A Strong Medical & Scientific Foundation
Guided by a world-renowned Scientific Advisory Board, InterCure, the maker of RESPeRATE, is committed to evidence-based medicine, clinical validation and a sound scientific foundation.
The Company has already demonstrated strong clinical validation for RESPeRATE. Clinical achievements for RESPeRATE, our non-drug medical device for lowering blood pressure, include:
• The first and only medical device indicated for the adjunctive treatment of hypertension.
• 14/9 mmHg average sustained blood pressure reductions within 8 weeks.
• No side effects, no drug interactions.
• Results of six clinical trials were published in peer-reviewed medical journals. [1-5] .
Average High Blood Pressure Reductions
Each point represents the office systolic blood pressure (BP) of the 141 patients in the RESPeRATE treatment group.
 Schein M, Gavish B, Herz M et al. "Treating hypertension with a device that slows and regularizes breathing: a randomized double-blind controlled study." J Human Hyperten 2001; 15(4): 271 - 278.
 Grossman E, Grossman A, Schein MH, Zimlichman R, Gavish B "Breathing-control lowers blood pressure." J Human Hyperten 2001; 15(4): 263 - 269.
 Rosenthal T, Alter A, Peleg E, Gavish B. "Device-guided breathing exercises reduce blood pressure and ambulatory and home measurement." Am J Hyperten 2001; 14(1): 74 - 76.
 Giannattasio C, Failla M, Meles E, Gentile G, Grappiolo A and Mancia G “Efficacy of self treatment of hypertension at home with device-guided breathing.” Am J Hyperten 2002; 15(4,2)186A.
 Elliott W, Izzo J, Rosing D, Snyder C, White W, Alter A, Gavish B, and Black B “Hypertension reduction by device-guided breathing shows a dose-response relationship.” Am J Hyperten 2002; 15(4,2)186A.